Coronary artery calcium, HIV and inflammation in Uganda compared with the USA.

HIV coronary artery calcium inflammation sub-saharan africa

Journal

Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219

Informations de publication

Date de publication:
Historique:
received: 07 03 2019
revised: 11 04 2019
accepted: 26 04 2019
entrez: 21 6 2019
pubmed: 21 6 2019
medline: 21 6 2019
Statut: epublish

Résumé

To compare the prevalence of detectable coronary artery calcium (CAC) among higher risk, older people living with HIV (PLWH) and uninfected persons in Uganda versus the USA, and second to explore associations of CAC with HIV-specific variables and biomarkers of inflammation. This cross-sectional study of 430 total subjects compared 100 PLWH on antiretroviral therapy and 100 age-matched and sex-matched HIV-uninfected controls in Uganda with 167 PLWH on antiretroviral therapy and 63 uninfected controls in the USA. Multivariable logistic regression was used to examine associations with detectable CAC (CAC >0). Compared with US subjects, Ugandans were older (mean age 56 vs 52 years) and were more likely to have diabetes (36% vs 3%) and hypertension (85% vs 36%), but were less likely to be male (38% vs 74%) or smokers (4% vs 56%). After adjustment for HIV serostatus, age, sex and traditional risk factors, Ugandans had substantially lower odds of CAC >0 (adjusted OR 0.07 (95% CI 0.03 to 0.17), p<0.001). HIV was not associated with CAC >0 in either country (p>0.1). Among all PLWH, nadir CD4 count was associated with the presence of CAC, and among Ugandans soluble intercellular adhesion molecule (p=0.044), soluble CD163 (p=0.004) and oxidised low-density lipoprotein (p=0.043) were all associated with the presence of CAC. Ugandans had a dramatically lower prevalence of any coronary calcification compared with US subjects. The role of HIV infection and inflammation as risk factors for subclinical coronary disease in sub-Saharan Africa merits further investigation.

Identifiants

pubmed: 31218009
doi: 10.1136/openhrt-2019-001046
pii: openhrt-2019-001046
pmc: PMC6546194
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Pagination

e001046

Subventions

Organisme : NHLBI NIH HHS
ID : K23 HL123341
Pays : United States
Organisme : NINR NIH HHS
ID : R01 NR012642
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL141053
Pays : United States

Déclaration de conflit d'intérêts

Competing interests: CTL has received a research grant from Gilead Sciences. MB has received a research grant from Sanofi and speaker fee from Boston Scientific. GAM has received grant support and is a consultant for Gilead, ViiV and Merck. No other authors have any disclosures relevant to the content of this manuscript.

Références

J Infect Dis. 2003 May 15;187(10):1534-43
pubmed: 12721933
JAMA. 2004 Jan 14;291(2):210-5
pubmed: 14722147
N Engl J Med. 2008 Mar 27;358(13):1336-45
pubmed: 18367736
Circulation. 2008 Apr 1;117(13):1627-9
pubmed: 18378624
AIDS Res Hum Retroviruses. 2009 Sep;25(9):877-82
pubmed: 19689195
Circ Cardiovasc Genet. 2009 Dec;2(6):629-36
pubmed: 20031644
Eur Heart J. 2010 Mar;31(6):642-8
pubmed: 20176800
AIDS. 2010 Jul 31;24(12):1897-905
pubmed: 20543654
J Infect Dis. 2011 Oct 15;204(8):1227-36
pubmed: 21917896
AIDS. 2012 Jun 1;26(9):1115-20
pubmed: 22382147
Nephrology (Carlton). 2012 Sep;17(7):607-15
pubmed: 22515484
AIDS. 2013 May 15;27(8):1263-72
pubmed: 23324657
Vasc Health Risk Manag. 2013;9:509-16
pubmed: 24043942
J Am Coll Cardiol. 1990 Mar 15;15(4):827-32
pubmed: 2407762
Ann Intern Med. 2014 Apr 1;160(7):458-67
pubmed: 24687069
AIDS. 2014 Apr 24;28(7):969-77
pubmed: 24691204
J Infect Dis. 2015 Apr 15;211(8):1219-28
pubmed: 25362192
J Infect Dis. 2016 Feb 1;213(3):370-8
pubmed: 26347573
AIDS. 2016 Feb 20;30(4):667-70
pubmed: 26636926
Open Forum Infect Dis. 2016 Feb 09;3(1):ofw032
pubmed: 26989755
PLoS One. 2017 Jan 13;12(1):e0169986
pubmed: 28085961
Lancet. 2017 Apr 29;389(10080):1730-1739
pubmed: 28320601
Curr Opin HIV AIDS. 2017 Nov;12(6):540-547
pubmed: 28799997
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
BMC Public Health. 2017 Dec 15;17(1):954
pubmed: 29246206
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):458-464
pubmed: 29652762
J Infect Dis. 2018 Aug 14;218(6):922-926
pubmed: 29718342
Circulation. 2018 Sep 11;138(11):1100-1112
pubmed: 29967196

Auteurs

Ben Alencherry (B)

Medicine and Pediatrics, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.

Geoffrey Erem (G)

Radiology, St Francis Hospital Nsambya, Kampala, Uganda.
Radiology and Medicine, Makerere University College of Health Sciences, Kampala, Uganda.

Grace Mirembe (G)

HIV Medicine, Joint Clinical Research Centre, Kampala, Uganda.

Isaac Ssinabulya (I)

Radiology and Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Cardiology, Uganda Heart Institute, Kampala, Uganda.

Chun-Ho Yun (CH)

Radiology, Mackay Memorial Hospital, Taipei, Taiwan.

Chung-Lieh Hung (CL)

Cardiology, Mackay Memorial Hospital, Taipei, Taiwan.

Mark J Siedner (MJ)

Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Medicine, Harvard Medical School, Boston, Massachusetts, USA.

Marcio Bittencourt (M)

Division of Internal Medicine, University Hospital, Sao Paulo, Brazil.

Cissy Kityo (C)

HIV Medicine, Joint Clinical Research Centre, Kampala, Uganda.

Grace A McComsey (GA)

Medicine and Pediatrics, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Pediatric Infectious Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Chris T Longenecker (CT)

Cardiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Classifications MeSH